IRRITABLE BOWEL SYNDROME

Long term benefits of hypnotherapy for irritable bowel syndrome

W M Gonsalkorale, V Miller, A Afzal, P J Whorwell

Background and aims: There is now good evidence from several sources that hypnotherapy can relieve the symptoms of irritable bowel syndrome in the short term. However, there is no long term data on its benefits and this information is essential before the technique can be widely recommended. This study aimed to answer this question.

Patients and methods: 204 patients prospectively completed questionnaires scoring symptoms, quality of life, anxiety, and depression before, immediately after, and up to six years following hypnotherapy. All subjects also subjectively assessed the effects of hypnotherapy retrospectively in order to define their “responder status”.

Results: 71% of patients initially responded to therapy. Of these, 81% maintained their improvement over time while the majority of the remaining 19% claimed that deterioration of symptoms had only been slight. With respect to symptom scores, all items at follow up were significantly improved on pre-hypnotherapy levels (p<0.001) and showed little change from post-hypnotherapy values. There were no significant differences in the symptom scores between patients assessed at 1, 2, 3, 4, or 5+ years following treatment. Quality of life and anxiety or depression scores were similarly still significantly improved at follow up (p<0.001) but did show some deterioration. Patients also reported a reduction in consultation rates and medication use following the completion of hypnotherapy.

Conclusion: This study demonstrates that the beneficial effects of hypnotherapy appear to last at least five years. Thus it is a viable therapeutic option for the treatment of irritable bowel syndrome.
of HT, and therefore data were available for three different time points—that is, pre-HT, post-HT, and follow up.

**Statistical analysis**

Mean values (with SEM) were calculated for all scores in the IBS questionnaire and HAD Scale completed pre- and post-HT and at follow up. Intra-individual differences in scores between these time points, with positive and negative values denoting improvement or deterioration in scores, respectively, relative to the earlier time point, were compared by paired t test. Comparison between individual groups was performed using independent t test (two groups) or analysis of variance (more than two groups). For each item in the SAQ, data are given as the proportion (%) of patients rating each response category. Intra-individual comparisons were made using McNemars test and independent groups compared using χ² test. Spearman (ρ) correlation coefficients were calculated to assess relationships between variables. For further analysis, patients were subdivided into responders and non-responders, based on the response to SAQ(i), with responders defined as patients rating their symptoms either “very much better” or “moderately better” at the end of the course of HT and non-responders as those rating symptoms “slightly better” or less. Patients were also grouped according to the number of years that had lapsed since completing treatment.

Binary logistic regression analysis was performed to identify factors affecting “responder” status. In order to limit the number of variables examined at any one time, a stepwise analysis was carried out using a series of variable blocks, with blocks relating to pre-HT measures for all symptoms, quality of life, and HAD scores as well as age, gender, and bowel habit.

Overall scores for IBS symptoms and extra-colonic features were treated as the primary outcomes. For the purpose of comparing secondary endpoints—that is, the individual measures making up these overall scores—only differences at the 0.1% (p<0.001) were interpreted as showing reasonable evidence of a true difference, instead of adjusting for multiple comparisons.

**RESULTS**

**Return rate**

Of the 273 questionnaires 204 were returned, representing a 75% return rate. These were reasonably equally distributed according to the time since completing treatment (1–2 years ago: 22.4%; 2–3 years: 18.4%; 3–4 years: 27.8%; 4–5 years: 21.4%; ≥5: 10.0%).

**Subjective assessment questionnaire**

**Improvement after hypnotherapy (SAQ(i))**

There were 106 (52.0%) patients who reported their symptoms as “very much better” at the end of the course of HT, 39 (19.1%) as “moderately better”, 32 (15.7%) as “slightly better”, while 27 (13.2%) reported no change in symptoms. No patients reported worsening of symptoms. Patients in whom symptoms were very much or moderately better (71.1% of total) were then defined as “responders”, and those with only slight improvement or no change as “non-responders”.

**Progress in symptoms since completing HT (SAQ(ii))**

Subdividing according to responder status as above, 81.3% of responders maintained the improvement gained, with the majority stating that their symptoms had improved even further (29.2% improved “much more”, 24.3% “moderately more”, 11.1% “slightly more”, and 16.7% “about the same as at the end of HT”). The remaining 18.7% had experienced mostly slight deterioration in symptoms. More responders than non-responders stated that symptoms had continued to improve after finishing HT (responders (R) vs non-responders (NR): 64.6% v 35.0%, χ² = 13.54, p<0.001) and symptom improvement was mainly rated as slight for these non-responders. The majority of non-responders, therefore, had no improvement in symptoms during the follow up period, with 49.1% being about the same as at the end of treatment (that is, about the same or only slightly improved compared with before HT) and 15.8% slightly worse.

**IBS questionnaires**

**IBS symptoms**

Scores from pre- and post-HT IBS questionnaires were compared in patients returning and not returning follow up questionnaires, in order to ensure that those returning these questionnaires were representative of the patient group as a whole. No differences in symptom severity before treatment or in initial improvement after HT emerged. Questionnaires returned (n=204) vs not returned (n=69); pre-HT (mean, SEM): pain severity 56.1 (1.9) v 60.1 (2.6); pain frequency 55.0 (2.4) v 64.1 (3.3); bloating 61.0 (1.9) v 61.8 (2.9); bowel habit dissatisfaction 71.6 (1.8) v 73.0 (2.4); life interference 72.5 (1.4) v 75.1 (1.7); overall score 314.2 (6.1) v 330.4 (8.6), all p>0.05. Pre-HT/post-HT intra-individual differences (mean, 95% confidence interval (CI)); pain severity 25.5 (21.5 to 29.5) v 27.2 (22.0 to 32.4); pain frequency 23.8 (19.1 to 28.6) v 35.3 (28.5 to 42.1); bloating 29.4 (25.5 to 33.4) v 31.9 (26.7 to 37.2); life interference 33.2 (29.4 to 36.9) v 31.1 (25.7 to 36.6); overall score 144.1 (128.8 to 159.4) v 151.3 (129.2 to 173.5), all p<0.05, except pain frequency where p=0.005.

Intra-individual differences in scores between the three different time points (that is, pre-HT, post-HT, and follow up) in the 204 patients for whom follow up data were obtained (figure 1) showed that all symptoms as well as the overall score had improved immediately after HT and remained better at follow up (pre-HT/post-HT and pre-HT/follow up intra-individual differences, all p<0.001). Symptoms had increased slightly at follow up compared with post-HT levels but this was significant only for bloating and bowel habit.
dissatisfaction (post-HT/follow up intra-individual differences, both \( p<0.001 \)).

Patients’ rating of improvement in the SAQ was reflected in the IBS questionnaire scores with a direct correlation, firstly, between rating of improvement after HT, SAQ(i), and intra-individual differences in pre-HT/post-HT overall IBS scores (\( p = 0.433, p<0.001 \)), and, secondly, between rating of symptom progress since completing HT, SAQ(ii), and differences in post-HT/follow up overall IBS scores (\( p = 0.488, p<0.001 \)).

**Analysis according to responder status**

As shown in table 1, severity of IBS symptoms prior to HT was no different between the responders and non-responders (R v NR: all \( p>0.05 \)). However, mean scores for responders were significantly lower than those for non-responders both immediately after HT (all \( p<0.001 \)) and at follow up (all \( p<0.001 \), except pain severity (\( p<0.05 \)) and bloating (\( p<0.01 \)). Intra-individual differences in scores between the different time points (figure 2) shows that while some symptom measures were also significantly improved in the non-responder group post-HT and at follow up (bowel habit dissatisfaction and life interference \( p<0.001 \) at both time points), these changes were small compared with those in responders. Indeed, responders had greater reduction in symptom scores than non-responders both immediately after HT (pre-HT/post-HT intra-individual differences, R v NR: all \( p<0.001 \)) and at follow up (pre-HT/follow up intra-individual differences. R v NR: all \( p<0.001 \) except pain frequency, \( p<0.005 \)). Furthermore, no significant intra-individual differences between post-HT and follow up symptom scores occurred for non-responders (all \( p>0.05 \), showing that symptoms did not improve with the course of time.

**Analysis according to time lapsed since completing treatment**

There was no association between the time, in years, since responders had completed treatment and intra-individual differences in post-HT and follow up overall IBS score (\( p = -0.027, p = 0.752 \)), suggesting that those with a longer gap since treatment had maintained improvement just as well as those who had finished more recently. In addition, there were no marked differences in overall IBS scores (table 2) between the different time intervals either before HT (\( p = 0.310 \)) or at follow up (\( p = 0.458 \)) or in the pre-HT/follow up intra-individual differences in this score (\( p = 0.781 \)).

**Table 1 IBS symptom scores**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Pre-HT</th>
<th>Post-HT</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>NR</td>
<td>R</td>
</tr>
<tr>
<td>Pain severity</td>
<td>58.0 (2.2)†</td>
<td>51.4 (3.6)</td>
<td>26.4 (1.9)**</td>
</tr>
<tr>
<td>Pain frequency</td>
<td>53.1 (2.8)†</td>
<td>59.3 (4.5)</td>
<td>22.8 (2.6)**</td>
</tr>
<tr>
<td>Bloating</td>
<td>61.0 (2.2)†</td>
<td>60.8 (3.8)</td>
<td>27.1 (2.1)**</td>
</tr>
<tr>
<td>BH dissatisfaction</td>
<td>71.1 (2.1)†</td>
<td>72.6 (3.4)</td>
<td>35.6 (1.8)**</td>
</tr>
<tr>
<td>Life interference</td>
<td>71.4 (1.8)†</td>
<td>75.2 (2.7)</td>
<td>32.2 (1.9)**</td>
</tr>
<tr>
<td>Overall score</td>
<td>312.2 (7.4)†</td>
<td>318.2 (11.0)</td>
<td>143.6 (8.3)**</td>
</tr>
</tbody>
</table>

Irritable bowel syndrome (IBS) symptom scores (mean, SEM) shown for responders (R) and non-responders (NR), as measured in IBS questionnaire (VAS 0–100 mm), completed at the time points shown. For data in this table (and similarly in all tables), overall score is treated as the primary outcome and therefore no adjustments are made for multiple comparisons. “Unadjusted” comparisons for individual symptoms significant at the 0.1% level (\( p<0.001 \)) assumed significant at the 5% level if multiple comparison adjustments were made.

\*\( p<0.05 \), \*\( p<0.01 \), **\( p<0.001 \), ***\( p<0.001 \); R v NR.

BH, bowel habit; HT, hypnotherapy.

Figure 2 Intra-individual differences in IBS symptom scores for responders and non-responders between the different time points shown. Data expressed as mean (95% confidence interval (CI)), with positive and negative values denoting reduction and increase in score relative to earlier time point. (Mean values of scores at these time points are given in table 1.) Overall score treated as the primary outcome and therefore no adjustment is made for multiple comparisons. “Unadjusted” comparison for individual symptoms significant at the 0.1% level are assumed to be significant at the 5% level if multiple comparison adjustment made, \( p<0.05 \), **\( p<0.01 \), ***\( p<0.001 \) (intra-individual difference); \( p<0.005 \), **\( p<0.001 \) (responders v non-responders).

**Extra-colonic symptoms**

Severity of extra-colonic symptoms before HT was similar for both responders and non-responders (table 3). Responders had significant improvement in individual symptoms and overall score after HT (pre-HT/post-HT intra-individual differences, all \( p<0.001 \)) and most of these remained better than pre-HT levels at follow up (pre-HT/follow up intra-individual differences all \( p<0.001 \), except urinary symptoms, thigh pain, and bodily aches, \( p<0.05 \)). Although non-responders had significant improvement in overall extra-colonic score and some individual symptoms immediately after HT (pre-HT/post-HT intra-individual differences: overall score, nausea, excess wind, lethargy all \( p<0.001 \)), this had deteriorated at follow up. Responders had more pronounced improvement in overall score than non-responders, both post-HT and at follow up (intra-individual differences, R v NR: pre-HT/post-HT \( p<0.001 \); pre-HT/follow up: \( p<0.005 \)) and for a number of individual symptoms after HT, including excess wind (pre-HT/follow up intra-individual differences, R v NR: \( p<0.001 \)), lethargy, backache, and...
Improvement was overall greater in the responder group, (10.7 (0.4) vs 6.7 (0.3)). Intra-individual differences (mean (95%CI): 10.7 (0.4) vs 6.7 (0.3)) were not significant at follow up only for mood (p = 0.001; pre-HT/follow up all p < 0.001). Improvement occurred in responders both after HT and at follow up, while fewer non-responders were anxious post-HT only (HAD “A” > 9 (anxious): Pre-HT v post-HT: R: 59.0% v 24.4%, p < 0.001; NR: 48.3% v 28.1%, p = 0.008; versus follow up: R: 31.9%, p < 0.001; NR: v 37.3%, p < 0.010; HAD “D” > 9 (depressed): Pre-HT v post-HT: R: 20.7% v 5.5%, p < 0.001; NR: 18.6% v 11.9%, p < 0.042; versus follow up: R: 9.0%, p = 0.002; NR: 13.6%, p = 0.549, McNemar’s test).

### Quality of life, anxiety, and depression

Quality of life measures before HT were no different for responders and non-responders (table 4). Although there was some improvement in the non-responder group immediately after HT (pre-HT/post-HT intra-individual differences, all p < 0.005, physical well being and control p < 0.001), this was significant at follow up only for mood (p < 0.005). Improvement occurred in responders both after HT and at follow up compared with pre-HT levels (intra-individual differences: pre-HT/post-HT all p < 0.001; pre-HT/follow up all p < 0.001, social/relationships p < 0.005) and this was more marked than in non-responders, particularly for psychic and physical well being (R v NR: pre-HT/post-HT p < 0.001; pre-HT/follow up p < 0.01).

HAD scores for anxiety and depression were similar in both patient groups before HT (R v NR: HAD “A” anxiety (mean [SEM]): 10.7 (0.4) v 9.8 (0.6), p = 0.184; HAD “D” depression: 6.7 (0.3) v 6.8 (0.4), p = 0.798). Scores had improved in both groups post-HT and were still better than pre-HT levels at follow up (intra-individual differences (mean [95%CI]): pre-HT/post-HT: anxiety: 4.1 (3.5 to 4.7), NR: 2.4 (1.4 to 3.3); depression: R: 3.4 (2.8 to 4.0), NR: 1.7 (0.9 to 2.6), all p < 0.001; pre-HT/follow up: anxiety, R: 2.7 (2.0 to 3.3), p < 0.001; NR: 1.5 (0.5 to 2.5), p = 0.003; depression, R: 2.5 (1.9 to 3.2), NR: 1.4 (0.7 to 2.2), both p < 0.001).

Improvement was overall greater in the responder group, particularly post-HT (R v NR: anxiety and depression, both p = 0.002) but less evident at follow up (R v NR: anxiety: p = 0.068; depression, p = 0.031). Fewer responders were significantly anxious or depressed (HAD scores > 9) after HT and at follow up, while fewer non-responders were anxious post-HT only (HAD “A” > 9 (anxious): Pre-HT v post-HT: R: 59.0% v 24.4%, p < 0.001; NR: 48.3% v 28.1%, p = 0.008; versus follow up: R: 31.9%, p < 0.001; NR: v 37.3%, p < 0.010; HAD “D” > 9 (depressed): Pre-HT v post-HT: R: 20.7% v 5.5%, p < 0.001; NR: 18.6% v 11.9%, p < 0.042; versus follow up: R: 9.0%, p = 0.002; NR: 13.6%, p = 0.549, McNemar’s test).

### Use of medication

Medication taken before HT included antispasmodics (42.0% of all patients on medication), antidiarrhoeals (23.2%), laxatives (12.3%), bulking agents (9.4%), antidepressants (10.9%), with 27% taking at least two types of medication. A similar proportion of responders and non-responders were taking medication before HT but fewer responders were on medication during follow up (R v NR: Pre-HT: 67.6% v 67.8%, χ² = 0.03, p = 0.856; during follow up: 36.6% v 55.9%, χ² = 6.27, p = 0.012). Of those patients continuing to take medication, more responders stated they had taken it less often than before (“less often”, “about same”, “more often”: R v NR (%): GP/IBS symptoms: 87.9%, 10.7%, 1.4% v 50.9%, 45.6%, 3.5%, χ² = 31.75, p < 0.001; Consultant/IBS symptoms: 83.3%, 13.7%, 3.7% v 54.8%, 40.5%, 4.8%, χ² = 13.41, p = 0.001; GP/other symptoms: 61.2%, 32.6%, 6.2% v 21.8%, 63.6%, 14.5%, χ² = 24.10, p < 0.001).

While proportionately more non-responders than responders with low anxiety and depression scores (HAD scores < 10) at follow up were taking antidepressants and/or anxiolytics (NR v R: 21.1% v 6.0%, p < 0.001) these represented only a minority of non-responders with low scores, since 63% and 80% of this group had low HAD “A” and “D” scores, respectively.

### Factors influencing initial response to hypnotherapy

There were no differences between responders and non-responders in any baseline measures of symptoms, quality of life, or HAD scores (tables 1, 3, and 4 and HAD results section) but more males than females were non-responders.
Hypnotherapy and irritable bowel syndrome

was no correlation between symptom change and frequency included all of the responders and 76.3% of non-responders. including dietary changes, alternative medicines, yoga, and The continued improvement seen in responders cannot be only: 42.4% v 25.3%, χ² = 4.63, p = 0.031). Although more males had diarrhoea predominant bowel habit (males v females, bowel habit type: constipation 12.8% v 25.3%, diarrhoea 51.3% v 24.8%, alternating 35.9% v 49.7%, χ² = 10.77, p = 0.005), no more non-responders were found with this or any other bowel habit type, either for patients as a whole or for males (constipation v diarrhoea v alternating: all patients, R: 69.6% v 73.3% v 71.3%; NR 30.4% v 26.7% v 28.7%, χ² = 0.19, p = 0.911; males: R: 40.0% v 60.0% v 57.1%; NR: 60.0% v 40.0% v 42.9%, χ² = 0.66, p = 0.721). Non-responders were also overall slightly older than responders (mean age (SEM), years: R v NR: 45.1 (1.2) vs 50.3 (1.8), p = 0.017). However, binary logistic regression analysis identified only gender as having a significant relationship with responder status (OR (95% CI): 0.30 (0.16 to 0.97), p = 0.042).

Continued practice of hypnotherapy techniques during follow up

More responders than non-responders continued to practise HT techniques after treatment (R % patients): 85% v 58%, p<0.001), although both groups had a similar pattern of practice (R v NR: with tape only: 38.7% v 36.4%; without tape: 42.4% v 42.5%; both with/without tape: 18.9% v 21.1%; χ² = 0.24, p = 0.970). There was no difference in symptom change during follow up between patients who still practised and those who did not (intra-individual difference in post-HT/follow up overall IBS score (mean (SEM)), practice v no practice: all patients: −19.5 (16.6) v −27.4 (7.8), p = 0.392; R only: −24.8 (32.6) v −31.9 (8.7), p = 0.628). Similarly, there was no correlation between symptom change and frequency of practice (all patients: ρ = 0.027, p = 0.777; R only: ρ = 0.067, p = 0.572).

Other considerations

The continued improvement seen in responders cannot be explained by the use of other treatments after finishing HT. Only 14 (9.7%) of responders had tried other treatments, including dietary changes, alternative medicines, yoga, and reflexology and found these helpful. Of all patients, 93.1% considered that the course of HT had been worthwhile, which included all of the responders and 76.3% of non-responders.

DISCUSSION

This study presents the first long term follow up of a large number of patients who have undergone hypnotherapy for IBS symptoms. Immediately after HT, 71% of patients considered their symptoms very much or moderately better and these patients were defined as “responders”. Of these initial responders, 81% maintained the benefit of treatment or reported further improvement. In contrast, non-responders, with only slight or no improvement in symptoms with HT, had little or no change in symptoms over the follow up period.

There was a good correlation between the SAQ ratings and the objective symptom scores. IBS symptom scores were significantly improved after HT and remained so at follow up, with only a slight deterioration compared with post-HT levels. The beneficial effects did not appear to decline with time since patients who had finished treatment more than five years ago maintained symptom improvement just as well as those who had completed only a year ago. Similarly, extra-colonic features, quality of life, anxiety, and depression scores were still better at follow up compared with pre-HT levels. Interestingly, all patients reported taking less medication and had consulted less often for IBS and other symptoms, but this was particularly striking for the responder group.

The subdivision of patients into “responders” and “non-responders”, based on the SAQ rating of symptom change, was undertaken in order to concur with the current practice of using a subjective global assessment as a primary outcome in clinical trials in functional bowel disorders.16 It also facilitated further analysis of the data, and indeed revealed that there were clear differences between responders and non-responders in terms of IBS and other symptom scores, consultation rates, and use of medication after treatment.

The SAQ was only completed at follow up, hence requiring patients to assess the effects of HT retrospectively and therefore the reliability of their reports could be called into question. However, the fact that the SAQ correlated with changes in symptom rating from the IBS questionnaires would indicate that the SAQ assessments are a reliable reflection of treatment outcome. Similarly, patients’ reports of consultation rates and use of medication must be interpreted with some caution. However, one could determine the number of patients who had stopped medication after HT, since medication was recorded at the start of HT and at follow up. Reports in terms of fewer consultations and less medication were markedly different between responders and non-responders, suggesting that these cannot be explained entirely by recall bias.

The return rate in this study was 75%. These patients can be considered to be representative of all patients contacted since their pre-HT IBS symptom scores and improvement immediately after HT were similar to the patients who did not return the follow up questionnaires. This study was an audit of patients who had undergone hypnotherapy and hence there was no control group, which may be considered a weakness to the study, although it is difficult to conceive how one could have been included. There is known to be a high level of placebo response in IBS patients which can last for at least three months.17 However, the improvement seen in this study lasted at least one year and was at the same level in patients after five or more years, making a placebo effect very unlikely. In addition, the fact that non-responders did not exhibit significant improvement during the follow up period makes it very unlikely the improvements observed in the

### Table 4 Quality of life measures

<table>
<thead>
<tr>
<th></th>
<th>Pre-HT</th>
<th>Pre-HT/Post-HT</th>
<th>Pre-HT/follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>NR</td>
<td>R</td>
</tr>
<tr>
<td><strong>Psychic well being</strong></td>
<td>50.3 (1.8)††</td>
<td>55.1 (3.1)</td>
<td>27.6 (23.9 to 31.4)*** ††</td>
</tr>
<tr>
<td><strong>Physical well being</strong></td>
<td>47.2 (1.7)††</td>
<td>45.1 (2.7)</td>
<td>21.8 (18.6 to 25.0)*** ††</td>
</tr>
<tr>
<td><strong>Mood</strong></td>
<td>48.9 (1.6)††</td>
<td>47.4 (2.0)</td>
<td>19.9 (16.4 to 23.4)*** ††</td>
</tr>
<tr>
<td><strong>Control</strong></td>
<td>53.8 (1.9)††</td>
<td>59.2 (3.4)</td>
<td>18.2 (14.8 to 21.5)*** ††</td>
</tr>
<tr>
<td><strong>Social/relationships</strong></td>
<td>68.6 (1.6)††</td>
<td>67.1 (2.9)</td>
<td>10.8 (8.6 to 18.6)*** ††</td>
</tr>
</tbody>
</table>

Data shown for responders (R) and non-responders (NR) as time mean scores (SEM) and intra-individual differences (mean (95% CI)) between time points.

Note: In contrast with other symptom scores, higher values in quality of life measures signify improvement; positive and negative values in intra-individual differences denote reduction (deterioration) and increase (improvement) in scores, respectively, relative to earlier time point.

*p < 0.05, †p < 0.005, ††p < 0.001, †††p < 0.05 (versus pre-HT), ††††p < 0.01, †††††p < 0.005 (R v NR).

(males v females: R: 57.5% v 74.7%; NR: 42.5% v 25.3%, χ² = 4.63, p = 0.031).
responder group were due to the natural course of the condition. The favourable response to HT reported here is unlikely to be influenced to any great extent by the fact that treatment was at a specialist centre providing this treatment, since independent studies at other centres have also shown beneficial results with HT.10-12 Therefore, we believe our results could be generalised to the treatment of IBS patients in general. Out of all the pre-HT measures and demographic features examined with regression analysis, only gender was significantly associated with responder status, with males being more likely to be non-responders and this is in keeping with our previous observations.13

Very little deterioration occurred in IBS symptoms over time, although some of the other measures, such as certain extra-colonic symptoms, quality of life, and scores for anxiety and depression, did show some attrition, but most of these were still better at follow up than before treatment. Quality of life and psychological well being are influenced by many other factors such as life events, irrespective of gastrointestinal problems and it is possible that any of these could have been operating within an individual since treatment, thus contributing to the change in these scores. Anxiety and depression scores were significantly lower both post-HT and at follow up in both responders and non-responders, although the proportion of patients who could be classified as significantly anxious or depressed was only lower in responders. This would suggest that even though non-responders did not improve in terms of IBS symptoms, they did derive some benefit psychologically. This is unlikely to be an effect of taking anxiolytics or antidepressants, since only a relatively small proportion of these non-responders were taking such medication after treatment. It is also interesting to note that nearly all patients considered the hypnotherapy to have been worthwhile, so that even non-responders felt that they had benefited in some way even though their symptoms had not altered with treatment.

Maintained improvement of symptoms did not appear to have any association with whether or not or how often responders continued to practise hypnotherapeutic techniques following treatment, although only 15% of responders discontinued practice. The reason for this somewhat unexpected finding is not readily apparent and does raise the question whether continued practice is necessary for any particular individual to maintain benefit. It may suggest that those who did well with HT yet did not continue to practise overtly have developed the ability to continue using their hypnotic skills at a subconscious level.

In conclusion, this study confirms that the beneficial effects of HT are long lasting, with continued improvement in symptoms, thus giving patients better control over their condition, although it may be less useful for male patients. A potential criticism for the use of hypnotherapy as a treatment for IBS has been that it is costly to provide because of the demands on therapists’ time. However, because of its sustained effects in the majority of patients, costs of treatment could be rapidly offset by the ensuing reduction in cost of medication and other healthcare demands.

APPENDIX 1

**IBS QUESTIONNAIRE**

Items in the questionnaire were scored using a visual analogue scale of 0–100 mm. Increased severity of IBS symptoms and extra-colonic features was indicated by a higher score, whereas increased impairment of quality of life measures was denoted by a lower score. Overall scores were calculated as the sum of the following individual items, adjusted as necessary to give a maximum score as indicated:

**Overall IBS score** (maximum 500; sum of 5 items): pain severity, pain frequency, distension, bowel habit dissatisfaction, life interference

**Overall extra-colonic score** (maximum 500; sum of 10 items +2): nausea/vomiting, early satiety, headaches, backache, excess wind, heartburn, bodily pains, urinary symptoms, thigh pain, lethargy.

**QUALITY OF LIFE**

The value of each quality of life measure was derived from the mean of the individual items shown in parentheses, to give a maximum score of 100.

- Psychic well being (coping with problems, confidence, usefulness, security)
- Physical well being (sleep, energy levels, aches and pains, feeling physically well)
- Mood (irritability, worrying, hopefulness, enjoyment of life)
- Locus of control (feeling in control of life, helplessness, ability to make decision)
- Social/relationship (relationships with family/partner, ability to maintain friendships, inferiority, feeling wanted, enjoyment of leisure).

**APPENDIX 2**

**SUBJECTIVE ASSESSMENT QUESTIONNAIRE (SAQ)**

This is a simple questionnaire devised in the Unit asking patients to rate the effects of HT on symptoms, consultation rates and use of medication etc, using Likert-type responses, as shown below.

**IBS symptoms**

(i) Compared with how you felt before HT, how would you rate your symptoms were at the end of the course of HT?

- very much better, moderately better, slightly better, about the same, slightly worse, moderately worse, very much worse

(ii) Compared with how your symptoms were at the end of the course of HT, would you say that since completing treatment your symptoms have:

- continued to: improve much more, moderately more, a little more; remained about same as at end of HT;
- gone: slightly worse, moderately worse, much worse.

**Consultation rates**

Since HT, have you had to consult:

(a) your GP (b) a hospital consultant about IBS symptoms:

- more often, about the same, less often (than before)

(c) your GP about other symptoms:

- more often, about the same, less often (than before).

**Use of medication**

(a) Do you currently take medication for IBS symptoms?

- Yes, No (If yes, please specify)

(b) Do you take medication:

- more often, about the same, less often (than before)
(Information on any medication taken before starting the course of HT was recorded at the time.)

4. Continued practice
Do you still practise HT techniques? Yes, No If so, do you practise:
(a) using tape, on own
(b) daily, several times/week, several times/month, rarely

5. Did you consider the course of HT to be worthwhile? Yes, No

6. (a) Have you tried any other treatment/therapy since HT to relieve IBS symptoms? Yes, No
(b) If so, what?
(c) Did you find this to be helpful? Yes, No

ACKNOWLEDGEMENTS
We wish to thank the other staff of the Hypnotherapy Unit who treated some of the patients used in this study: Mrs P Cooper, Mrs P Cruickshanks, Mrs J Randles, and Mrs V Whelan. We also thank Mrs Julie Morris, Head of Medical Statistics, University Hospital of South Manchester, for help with statistical analysis.

Authors’ affiliations
W M Gonsalkorale, V Miller, A Afzal, P J Whorwell, Department of Medicine, University Hospital of South Manchester, Manchester, UK

REFERENCES
Long term benefits of hypnotherapy for irritable bowel syndrome

W M Gonsalkorale, V Miller, A Afzal and P J Whorwell

Gut 2003 52: 1623-1629
doi: 10.1136/gut.52.11.1623

Updated information and services can be found at:
http://gut.bmj.com/content/52/11/1623

These include:

References
This article cites 15 articles, 2 of which you can access for free at:
http://gut.bmj.com/content/52/11/1623#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
  Irritable bowel syndrome (327)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/